Metastatic breast cancer remains challenging to treat, and most patients ultimately progress
on therapy. This acquired drug resistance is largely due to drug-refractory sub-populations …

Cancer is the leading cause of death worldwide. Despite improvements in diagnosis and
treatment over the past two decades, cancer continues to present a serious challenge to …

Drug resistance represents a major limitation to the long‐term efficacy of anti‐cancer
treatments. The commonly accepted view is that the selection of inheritable genetic …

Background The molecular mechanisms underlying innate tumor drug resistance, a major
obstacle to successful cancer therapy, remain poorly understood. In colorectal cancer …

The capacity of cancer to adapt to treatment and evolve is a major limitation for targeted
therapies. While the role of new acquired mutations is well-established, recent findings …

Evolution of resistance remains a barrier to successful therapy in most metastatic cancers
despite the increasing number of treatment options. A major driver of the evolutionary …

Cancer cells are remarkably resilient to therapies aimed at their elimination. The exploration
of pathways that sustain cancer cells and that allow cancer cells to become resistanthas …

Tumour evolution, which results in the existence of multiple distinct populations of cancer
cells within the same tumour and the same patient, is increasingly appreciated to have a key …

Despite the development of effective targeted agents for the treatment of cancer, targeted
therapies eventually fail in advanced, metastatic non-small cell lung cancer (NSCLC) as …

Cancer is composed of a major subpopulation of proliferative cells and a minor
subpopulation of highly adaptable cells. Although it is evident that cancer is an evolution like …